A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors
Key facts
- Who runs it
- University of Washington
- Where
- Seattle, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 4 Oct 2024
- Ended
- 29 May 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Cognitive Behavior Therapy for Insomnia
- Internet-Based Intervention
- Medical Device Usage and Evaluation
- Questionnaire Administration
- Text Message-Based Navigation Intervention
- Record updated
- 9 June 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Age ≥ 18 years and ≤ 80 years
- Prior diagnosis of stage I-III invasive breast cancer
- Female gender
- Clinically significant insomnia symptoms, defined as a Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance 8 T-score of 55 or greater
- Insomnia complaints lasting ≥ 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, indicating ability to perform activities of daily living
- Own a smartphone with Internet connectivity
- Willing and able to complete the intervention with personal smartphone
- Proficient in speaking and reading English
- Completed breast cancer treatment within past 5 years
Who cannot take part
- Prior diagnosis of restless leg syndrome, periodic leg movement disorder, narcolepsy, or rapid eye movement (REM) behavior disorder
- Actively receiving chemotherapy or radiation (endocrine therapy permitted)
- Previously received CBTi therapy with a professional therapist
- Use of prescribed sleep medication > 3 times per week
- Previously participated in user testing of the study intervention (Cecebot)
- Contraindications to CBTi including:; Active psychosis; Uncontrolled bipolar disorder; Severe depression; Active substance use disorder (moderate or greater severity)
- Current sleep apnea (treated or untreated)
- Current shiftwork
- Unwilling or unable to complete study procedures
Where in United States
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, United States
About the trial
What the trial wants to find out
This clinical trial evaluates the effect of conversational agent, Cecebot, on improving insomnia in stage I-III breast cancer survivors. Sleep disturbance ranks among the top concerns reported by breast cancer survivors and is associated with poor quality of life. Many breast cancer survivors also have decreased physical activity, which may also have a negative impact on sleep and quality of life. Cognitive behavioral therapy for insomnia (CBTi) and physical activity interventions have individually been reported to improve sleep and to have a positive impact on quality of life. Cecebot is a personalized short messaging service (SMS)-based behavioral intervention that combines CBTi and physical activity strategies that may improve sleep for breast cancer survivors.
The 2 groups in the trial
- GROUP I (Cecebot intervention)Treatment being tested
Patients receive sleep education SMS conversations and access to website content modules over 10 minutes 2-4 times per week, sleep compression SMS conversations QW, and wear activity tracker daily on weeks 1-6.
Treatment: Cognitive Behavior Therapy for Insomnia, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, and Text Message-Based Navigation Intervention
- GROUP II (waitlist control, Cecebot intervention)Treatment being tested
Patients receive sleep education SMS conversations and access to website content modules over 10 minutes 2-4 times per week, sleep compression SMS conversations QW, and wear activity tracker daily on weeks 7-12.
Treatment: Cognitive Behavior Therapy for Insomnia, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, and Text Message-Based Navigation Intervention
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Crossover Randomized Controlled Trial to Investigate the Acceptability and Efficacy of Cecebot, a Conversational Agent for Insomnia After Breast Cancer
- Publications
- Record updated
- 9 June 2026